Saturday, July 23, 2005

A Chronology of Anti-Depressant Warnings

It may not be widely known, but over the last two years there have been significant actions taken by regulatory agencies around the world to label, warn about and ban the drugs that psychiatrists are using to poison millions of children in the United States and around the world.  Yet the psychiatrists and the pharmaceuticals continue to produce, sell and inject them as fast as they can make a profit.
When one considers that the data on which these actions were taken was solely the studies done by psychiatrists in the pay of the pharmaceuticals, consider what an independent, outside study would reveal!
10 June 10 2003      
The British Medicine and Healthcare Products Regulatory Agency bans Paxil/Seroxat from use for people under the age of 18, after data emerged that there is an increase in self-harm and potentially suicidal behavior. The agency concluded that the potential benefit of the drug does not outweigh the risk.
15 July, 2003            
 Health Canada issues similar instructions not to prescribe Paxil to patients under 18. The maker of Paxil admitted that Paxil did not appear to work in children who were taking it. Reported adverse effects include suicidal thoughts and suicide attempts.
July 2003                  
France banned Paxil for use in children as well.
19 Sept 2003            
 The British Medicines and Healthcare Regulatory Agency (MHRA) announces a ban on Efexor (an SSRI) for Children, based on prior concealed evidence of some children becoming suicidal or homicidal taking SSRIs.
10 Dec 2003             
 The British MHRA ruled that SSRIs other than Prozac may not be prescribed to children. It also stated that Prozac helped only one child of 10. Prozac is to include in its labeling that it is “not recommended” for people under 18.
Early Feb 2004         
Health Canada issues advisory to anyone under 18 taking one of seven antidepressants to consult with their doctors.” Canada mandated warnings for side effects such as hostility, aggression and “self-harm” on SSRIs and SNRIs (Serontonin Norepinephrine Reuptake Inhibitors). The drugs are not approved for people under 18 in Canada, yet doctors used to prescribe them off-label.
18 October 2004      
 The FDA requires a black box warning on all antidepressants to warn against increased risk of suicidal behavior in children and adolescents, after studies indicated such an increased risk.
10 Dec 2004             
The European Committee for Medicinal Products for Human Use (CHMP) warned that there was an increased risk of suicidal behavior and thoughts with all SSRIs for children.
 The British National Institute for Clinical Excellence called on doctors to exercise more caution in prescribing antidepressants.
9 Feb 2005                
 Health Canada instructs the manufacturer of Adderall XP (ADHD drug) to withdraw the drug from the Canadian market due to association of the drug with sudden deaths, heart-related deaths and strokes in children and adults.
26 Apr 2005             
 European Medicines Agency (EMEA) concludes that SSRIs and SNRIs are unfit for use on children and adolescents to treat depression. It further recommended including warnings in labeling of the drugs about the risks, including suicidal behavior and thoughts, aggression, hostility and anger in children and young adults.
1 July 2005               
 FDA advisory to rewrite labels for attention deficit hyperactivity disorder drugs containing methylphenidate (including Ritalin) about psychiatric side effects of those drugs.  The advisory came after review of reports including suicidal thoughts, aggression and depression. The FDA also made public a study that indicates an increased risk of cancer later in the life of a person taking Ritalin as achild.
1 July 2005               
 FDA issues a recommendation that adults prescribed anti-depressants should be closely scrutinized for increased suicidal tendencies and behavior, citing studies linking anti-depressants to suicide risk. The FDA posted on its website a notice of higher-than-expected rates of suicide attempts in research with Eli Lilly’s new antidepressant, Cymbalta.


Post a Comment

<< Home